Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin

Summary

The optimal medical strategy for prevention of thromboembolic events after bioprosthetic aorta valve replacement (BAVR) remains controversial. The aim of this trial was to compare warfarin therapy (target INR of 2.0 to 3.0) against aspirin 150mg daily as antithrombotic therapy for the first three months after BAVR with or without concomitant coronary artery bypass grafting (CABG). The aim was to evaluate thromboembolic complications, bleeding complications and death.

Timeline

Start

2005-06

Primary completion

2012-03

Completion

2012-03

Drugs

Indications